TickerFacts.

Company research / MRVI

Maravai Lifesciences Holdings, Inc. (MRVI)

Build a valuation ↗↓ Download CSV

SEC name MARAVAI LIFESCIENCES HOLDINGS, INC. · CIK 0001823239 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Maravai Lifesciences Holdings, Inc. reported revenue of $185.74M. Revenue fell 28.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $208.78M.

Key ratios (year ended 2025-12-31)

18.3%
Gross margin
-115.9%
Operating margin
-70.4%
Net margin
-61.6%
Return on year-end equity
-28.3%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312024-09-302024-06-302023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$208.78M$185.74M$259.19Mn/an/a$288.94M$883.00M$799.24M$284.10M$143.14M
Cost of Revenue$135.93M$151.75M$150.88Mn/an/a$148.74M$168.96M$140.56M$79.65M$66.85M
Gross Profit$72.85M$33.99M$108.31Mn/an/a$140.20M$714.04M$658.68M$204.45M$76.29M
R&D Expense$15.22M$17.40M$19.22Mn/an/a$17.28M$18.37M$15.22M$9.30M$3.63M
Operating Income-$117.07M-$215.27M-$235.62Mn/an/a-$31.65M$574.22M$554.64M$119.90M$23.99M
Net Income-$77.39M-$130.77M-$144.85Mn/an/a-$119.03M$220.21M$182.04M$88.97M-$4.47M
EPS (Diluted)n/a-$0.90-$1.05n/an/a-$0.90$1.67$1.56$2.36-$0.03
Total Assets$603.75M$770.58M$1.01B$1.28B$1.44B$1.49B$2.28B$1.92B$1.27Bn/a
Total Liabilities$248.16M$397.87M$431.04M$665.56M$671.26M$697.57M$1.38B$1.37B$1.12Bn/a
Long-Term Debt$147.10M$291.77M$295.93Mn/an/a$524.15M$527.44M$530.59M$534.61Mn/a
Shareholders' Equity$204.62M$212.38M$325.29M$344.90M$434.73M$416.75M$545.22M$315.50M$88.51Mn/a
Cash & Equivalents$70.09M$216.89M$322.40M$578.16M$573.17M$574.96M$632.14Mn/an/an/a
Operating Cash Flow-$25.26M-$57.57M$7.46Mn/an/a$126.22M$535.98M$368.57M$152.19M$24.11M
Capital Expendituresn/a$13.15M$29.66Mn/an/a$65.55M$17.09M$14.85M$25.41M$17.15M
Free Cash Flown/a-$70.72M-$22.19Mn/an/a$60.67M$518.89M$353.72M$126.78M$6.97M
Share Repurchasesn/an/an/an/an/an/a$0$0$33.66M$0
Weighted Average Diluted Sharesn/a144.36M137.91Mn/an/a131.92M255.32M257.80M28.91M253.92M
EPS (Basic)n/a-$0.90-$1.05n/an/a-$0.90$1.67$1.59$7.43-$0.03

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView